Mintz advised Axoft, a neurotechnology company, on a $55 million Series A financing round. The funding will be used to expand Axoft’s clinical trials globally and progress US regulatory approval for its implantable Brain-Computer Interfaces (iBCIs).  

Given that neurological disorders are the leading cause of disability across the globe, iBCIs have the potential to transform how these conditions are assessed and treated by enabling greater access to brain activity than traditional exams or imaging. Better neural data will enable discovery of novel disease biomarkers, support personalized treatments, and power a new generation of AI models for brain health. 

The Mintz team was led by Joshua Fox and Alexander Civetta and included John Cheney, Robert Kidwell, Libby Decker, and Nicole Gaston.